<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442023000100003</article-id>
<article-id pub-id-type="doi">10.24875/rmn.22000048</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Type 2 diabetes mellitus as a determinant factor for the age of Parkinson&#8217;s disease onset]]></article-title>
<article-title xml:lang="es"><![CDATA[Diabetes mellitus tipo 2 como factor determinante de la edad de aparición de la enfermedad de Parkinson]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cervantes-Arriaga]]></surname>
<given-names><![CDATA[Amin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Esquivel-Zapata]]></surname>
<given-names><![CDATA[Oscar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escobar-Valdivia]]></surname>
<given-names><![CDATA[Emmanuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Romero]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muñuzuri-Camacho]]></surname>
<given-names><![CDATA[Marco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Medrano]]></surname>
<given-names><![CDATA[Ana J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Abundes-Corona]]></surname>
<given-names><![CDATA[Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Violante]]></surname>
<given-names><![CDATA[Mayela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,National Institute of Neurology and Neurosurgery Clinical Laboratory of Neurodegenerative Diseases ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,National Institute of Neurology and Neurosurgery Movement Disorder Clinic ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2023</year>
</pub-date>
<volume>24</volume>
<numero>1</numero>
<fpage>3</fpage>
<lpage>7</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442023000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442023000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442023000100003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: This study aims to identify whether type 2 diabetes mellitus (T2DM) impacts the age of Parkinson&#8217;s disease (PD) onset.  Methods: Consecutive people living with PD (PwP) with 2-4 years of disease duration were included and categorized according to the presence of T2DM. A 2:1 ratio randomization from the non-DM sample was performed. T2DM diagnosis was defined by a positive personal history of T2DM recorded in the medical files or reported by the subject, or the use of a hypoglycemic drug for glycemic control. A clinical assessment including the Movement Disorder Society Unified Parkinson&#8217;s disease rating scale and the Hoehn and Yahr was performed by a movement disorders specialist.  Results: One hundred and twenty-four non-T2DM PwP and 62 PwP with T2DM (PD-DM) were included in the study. No statistically significant differences between groups were found in motor and non-motor scores nor in disease duration. The mean age of the whole sample was 63.4 ± 11.9 years, with a mean PD duration of 3.4 ± 0.8 years. In the PD-DM group, the mean duration of T2DM was 12.4 ± 6.8 years, and T2DM was diagnosed 9.2 ± 6.8 years before the PD onset. The PD-DM group had an older age of PD onset (5.9 ± 1.6 year, p &lt; 0.001).  Conclusions: Patients with PD-DM had an older age at PD onset, suggesting a potential T2DM role in delaying the age of disease onset.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Se ha demostrado previamente una relación entre la enfermedad de Parkinson (EP) y la diabetes mellitus tipo 2 (DM2). La DM2 en personas con EP se asocia con un curso más agresivo de la enfermedad. Este estudio tiene como objetivo identificar si la DM2 tiene un impacto en la edad de inicio de la EP.  Métodos: Se incluyeron consecutivamente personas con enfermedad de EP (PCP) con una duración de entre dos y cuatro años y se clasificaron según la presencia de DM2. Se realizó una aleatorización de proporción 2:1 de la muestra No DM2. La evaluación clínica fue realizada por un especialista en trastornos del movimiento.  Resultados: Se incluyeron un total de 124 PCP no diabéticas y 62 PCP con DM2 (EP-DM). No se encontraron diferencias estadísticamente significativas en las puntuaciones motoras y no motoras ni en la duración de la enfermedad entre los grupos. El grupo EP-DM tuvo una mayor edad de inicio de la EP (5.9 ± 1.6 años, p &lt; 0.001) en comparación con el grupo No DM.  Conclusión: Los pacientes con EP-DM tenían una edad más avanzada al inicio de la EP, lo que sugiere un papel potencial de la DM2 en el retraso de la edad de inicio de la EP.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Parkinson disease]]></kwd>
<kwd lng="en"><![CDATA[Type 2 diabetes]]></kwd>
<kwd lng="en"><![CDATA[mellitus]]></kwd>
<kwd lng="en"><![CDATA[Age of onset]]></kwd>
<kwd lng="en"><![CDATA[Risk factors]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad de Parkinson]]></kwd>
<kwd lng="es"><![CDATA[Diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[Edad de inicio]]></kwd>
<kwd lng="es"><![CDATA[Factores de riesgo]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>GBD 2016 Neurology Collaborators Global</collab>
<article-title xml:lang=""><![CDATA[Global, regional, and national burden of neurological disorders, 1990-2016:a systematic analysis for the global burden of disease study 2016]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2019</year>
<volume>18</volume>
<page-range>459-80</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lipman]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Boykin]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Flora]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucose intolerance in Parkinson's disease]]></article-title>
<source><![CDATA[J Chronic Dis]]></source>
<year>1974</year>
<volume>27</volume>
<page-range>573-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cereda]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Barichella]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cassani]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Caccialanza]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pezzoli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical features of Parkinson disease when onset of diabetes came first:A case-control study]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2012</year>
<volume>78</volume>
<page-range>1507-11</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kotagal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Albin]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Koeppe]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Frey]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Bohnen]]></surname>
<given-names><![CDATA[NI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes is associated with postural instability and gait difficulty in Parkinson disease]]></article-title>
<source><![CDATA[Parkinsonism Relat Disord]]></source>
<year>2013</year>
<volume>19</volume>
<page-range>522-6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pagano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Polychronis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Giordano]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrara]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Niccolini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes mellitus and Parkinson disease]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2018</year>
<volume>90</volume>
<page-range>e1654-62</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kutty]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus]]></article-title>
<source><![CDATA[Mov Disord]]></source>
<year>2018</year>
<volume>33</volume>
<page-range>1967-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Postuma]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stern]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Poewe]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Olanow]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Oertel]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MDS clinical diagnostic criteria for Parkinson's disease]]></article-title>
<source><![CDATA[Mov Disord]]></source>
<year>2015</year>
<volume>30</volume>
<page-range>1591-601</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holford]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Nutt]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Kieburtz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shoulson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<collab>Parkinson Study Group</collab>
<article-title xml:lang=""><![CDATA[Disease progression and pharmacodynamics in Parkinson disease-evidence for functional protection with levodopa and other treatments]]></article-title>
<source><![CDATA[J Pharmacokinet Pharmacodyn]]></source>
<year>2006</year>
<volume>33</volume>
<page-range>281-311</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rusticus]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Lovato]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of sample size and variability on the power and Type I error rates of equivalence tests:a simulation study]]></article-title>
<source><![CDATA[Pract Assess Res Eval]]></source>
<year>2014</year>
<volume>19</volume>
<page-range>11</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iwagami]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shinozaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Introduction to matching in case-control studies and cohort studies]]></article-title>
<source><![CDATA[Ann Clin Epidemiol]]></source>
<year>2022</year>
<volume>4</volume>
<page-range>33-40</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hennessy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bilker]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Berlin]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Strom]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors influencing the optimal control to-case ratio in matched case-control studies]]></article-title>
<source><![CDATA[Am J Epidemiol]]></source>
<year>1999</year>
<volume>149</volume>
<page-range>195-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Martin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Blazquez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez-Sanchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arakaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bergareche-Yarza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chade]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expanded and independent validation of the movement disorder society-unified Parkinson's disease rating scale (MDS-UPDRS)]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2013</year>
<volume>260</volume>
<page-range>228-36</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kaur]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Grewal]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapies modulating insulin resistance in Parkinson's disease:a cross talk]]></article-title>
<source><![CDATA[Neurosci Lett]]></source>
<year>2021</year>
<volume>749</volume>
<page-range>135754</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murzi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Contreras]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Teneud]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Valecillos]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Parada]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[De Parada]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes decreases limbic extracellular dopamine in rats]]></article-title>
<source><![CDATA[Neurosci Lett]]></source>
<year>1996</year>
<volume>202</volume>
<page-range>141-4</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brauer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Athauda]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Girges]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vijiaratnam]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes medications and risk of Parkinson's disease:a cohort study of patients with diabetes]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2020</year>
<volume>143</volume>
<page-range>3067-76</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yue]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of Parkinson disease in diabetes mellitus:an updated meta-analysis of population-based cohort studies]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2016</year>
<volume>95</volume>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kandel]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gautam]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alaref]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jahan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes mellitus and Parkinson's disease:shared pathophysiological links and possible therapeutic implications]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2020</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[HQ]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[GQ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes and risk of Parkinson's disease:an updated meta-analysis of case-control studies]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chohan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Senkevich]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Bestwick]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Ciga]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 Diabetes as a determinant of Parkinson's disease risk and progression]]></article-title>
<source><![CDATA[Mov Disord]]></source>
<year>2021</year>
<volume>36</volume>
<page-range>1420-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rotermund]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Machetanz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The therapeutic potential of metformin in neurodegenerative diseases]]></article-title>
<source><![CDATA[Front Endocrinol (Lausanne)]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>400</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paudel]]></surname>
<given-names><![CDATA[YN]]></given-names>
</name>
<name>
<surname><![CDATA[Angelopoulou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Piperi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shaikh]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Othman]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging neuroprotective effect of metformin in Parkinson's disease:a molecular crosstalk]]></article-title>
<source><![CDATA[Pharmacol Res]]></source>
<year>2020</year>
<volume>152</volume>
<page-range>104593</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Islam]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Weng]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between statin use and risk of Parkinson's disease:evidence from 18 observational studies comprising 3.7 million individuals]]></article-title>
<source><![CDATA[J Pers Med]]></source>
<year>2022</year>
<volume>12</volume>
<page-range>825</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Akkala]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Klugarová]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pokorná]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Klugar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beta-adrenergic drugs and risk of Parkinson's disease:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Ageing Res Rev]]></source>
<year>2022</year>
<volume>80</volume>
<page-range>101670</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The significance of uric acid in the diagnosis and treatment of Parkinson disease:an updated systemic review]]></article-title>
<source><![CDATA[Med (Baltimore)]]></source>
<year>2017</year>
<volume>96</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
